C-UZS3Lyceum Pharmaceuticals
evolutionary genomics, experimental evolution, Drosophila models
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-UZS3
C-UZS3C-UZS3evolutionary genomics, experimental evolution, Drosophila models
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Lyceum Pharmaceuticals evolutionary genomics, experimental evolution, Drosophila models
Lyceum Pharmaceuticals grows out of co-founder Michael R. Rose's evolutionary biology research at the University of California, Irvine. The company applies quantitative genetics, experimental evolution, genome-wide sequencing, and statistical learning to aging and chronic disease drug discovery. Its site says it uses evolved Drosophila populations and genomic insights to identify pathways and candidate pharmaceuticals for chronic diseases of aging.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Lyceum Pharmaceuticals — Far from goals · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (2 programs at exploratory).…
Source: Deterministic